Coronary drug project
|
High Density Lipoprotein Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Clinical Trials |
|
Case Studies |
|
Coronary drug project On the Web |
|
American Roentgen Ray Society Images of Coronary drug project |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Rim Halaby, M.D. [2]
Official Title
Coronary Drug Project
Objective
To determine whether regular administration of lipid modifying drugs (clofibrate, nicotinic acid, estrogen, dextrothyroxine) to men with a documented myocardial infarction would result in significant reduction in total mortality over a five year period. Secondarily, to determine whether the degree to which these drugs changed serum lipids was correlated with any effect on mortality and morbidity rates; to gain further information on the long-term prognosis of myocardial infarction (by studying the control group as intensively as the treatment group); to acquire further experience and knowledge concerning the techniques and methodology of long-term clinical trials; to determine, in a substudy, the effectiveness of aspirin, a platelet inhibitor, in reducing recurrences of myocardial infarction.
Sponsor
National Heart, Lung, and Blood Institute (NHLBI)
Timeline
| Timeline | |
| Start Date | April 1965 |
| End Date | March 1985 |
| Status | Completed |
The previous information was derived from ClinicalTrials.gov on 08/18/2014 using the identification number NCT00000482.
Study Description
| Study Description | |
| Study Type | Interventional |
| Study Phase | Phase 3 |
| Study Design | |
| Allocation | Randomized |
| Masking | Double-Blind |
| Study Details | |
| Primary Purpose | Prevention |
| Condition | Cardiovascular diseases; coronary disease; heart diseases; myocardial infarction; myocardial ischemia |
| Intervention | Drug: estrogen Drug: clofibrate clofibrate |
| Population Size | 8,341 subjects |
The previous information was derived from ClinicalTrials.gov on 09/19/2013 using the identification number NCT00000482.
Eligibility Criteria
Inclusion Criteria
Men, ages 30-64, three months beyond most recent myocardial infarction